Monitor for potential dilutive financing given cash runway only through Q4 2026; Phase 1 updates in 2H 2026 could provide catalyst if positive, but near-term funding overhang likely weighs on the stock.
Price Chart
Executive Summary
GT Biopharma reported Q2 2026 EPS of -$0.11, missing consensus of -$0.08 by 37.5%, with no revenue. Cash runway of $5.1M is expected to fund operations only through Q4 2026, raising near-term financing concerns. Two Phase 1 TriKE trials are enrolling, with updates expected in 2H 2026.
Key Financial Metrics
Key Facts
- EPS -$0.11 vs consensus -$0.08 (-37.5% miss)
- Cash and equivalents $5.1M as of June 30, 2026, sufficient through Q4 2026
- R&D expenses $1.1M (up from $0.4M YoY), SG&A $3.4M (up from $1.1M YoY)
- Net loss $4.5M vs $30.2M in prior year (improvement due to non-recurring $28.7M Greenshoe liability in 2025)
- Phase 1 GTB-3650 (CD33) and GTB-5550 (B7-H3) trials enrolling; updates expected 2H 2026
Financial Impact
EPS miss of 37.5% on a small base; cash burn rate suggests need for financing within ~5 months
Risk Factors
- Cash runway limited to Q4 2026, likely requiring additional financing
- Clinical trial enrollment delays or negative data
- Potential Nasdaq delisting if stock price remains low
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3345280 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | 8-K | $9.00 $7.16 | ▲ +20.44% | ▲ +21.26% | $6.03 (+33.00%) |
Sep 3, 2026 29d ago | 8-K | $0.2524 $8.61 | ▲ +3311.25% | ▲ +3312.40% | $6.03 (+2289.07%) |
Aug 14, 2026 7w ago | Press Release | $0.2960 $0.2886 | ▲ +2.50% | ▲ +1.13% | $6.03 (−1937.16%) |
May 22, 2026 19w ago | 8-K | $0.4400 $0.4420 | ▼ −0.45% | ▲ +1.22% | $6.03 (−1270.45%) |
Apr 30, 2026 22w ago | S-1 | $0.3430 $0.3750 | ▼ −9.33% | ▼ −6.98% | $6.03 (−1658.02%) |
Apr 7, 2026 25w ago | 8-K | $0.4130 $0.3890 | ▼ −5.81% | ▼ −11.14% | $6.03 (+1360.05%) |
Mar 2, 2026 30w ago | Press Release | $0.4670 $0.4170 | ▼ −10.71% | ▼ −9.50% | $6.03 (+1191.22%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access